Matthew J. O’Brien, MD, MSc

Articles by Matthew J. O’Brien, MD, MSc

Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes

ByDavid T. Liss, PhD,Manisha Cherupally, MS,Matthew J. O’Brien, MD, MSc,Raymond H. Kang, MA,Cassandra Aikman, MPH,Amisha Wallia, MD, MS,Andrew J. Cooper, MSc,Eleena Koep, MS,Emily D. Parker, PhD, MPH,Ronald T. Ackermann, MD, MPH

December 12th 2023

Among adults with type 2 diabetes who started noninsulin second-line therapy, most modified treatment within 1 year. Discontinuation was by far the most common modification.

Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications

ByDavid T. Liss, PhD,Raymond H. Kang, MA,Nicola Lancki, MPH,Matthew J. O’Brien, MD, MSc,Amisha Wallia, MD, MS,Andrew J. Cooper, MSc,Sterling A. Harris, BA,Emily D. Parker, PhD, MPH,Ronald T. Ackermann, MD, MPH

March 9th 2021

Adults with type 2 diabetes who received nonsulfonylurea medications had relative increases in total costs. Receiving newer medication classes led to relatively decreased medical costs.

Latest Updated Articles

Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications
March 9th 2021
Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes
December 12th 2023

Matthew J. O’Brien, MD, MSc

Articles by Matthew J. O’Brien, MD, MSc

Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes

Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications

Latest Updated Articles

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Home-Based Heart Failure Care Shows Comparable Safety to Continued Inpatient Care

Cardiology Prices Vary Widely by Insurer and State

Voice Biomarkers Show Promise for Asthma, COPD Exacerbation Detection

Rethinking Cardiometabolic Risk: Deepak Bhatt, MD, MPH, MBA